drugset / Trial / NCT02261493

A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides

NCT02261493 ↗

Phase 3 Completed 787 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a safety and efficacy study of onabotulinumtoxinA in subjects with upper facial rhytides (forehead lines, glabellar lines, lateral canthal lines \[crow's feet lines\]).

Timeline

Start
2014-10-27
Primary completion
2015-06-03
Completion
2016-04-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic — Other

Indications

No indication recorded.